Lynn Symonds

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer

Lloye M. Dillon, Jennifer R. Bean, Wei Yang et al. · Oncogene · 2014 · 84 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +16

A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of Pten and Lkb1 Is Highly Responsive to mTOR Inhibition

Hailing Cheng, Pixu Liu, Fan Zhang et al. · Cancer Research · 2013 · 60 citations · Full text

Medicine, Cancer Biology, Oncology +17

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Lynn Symonds, Hannah M. Linden, Vijayakrishna K. Gadi et al. · Clinical Breast Cancer · 2018 · 36 citations

Medicine, Oncology, Pharmacology +14

The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer

Jennifer R. Bean, Sarah R. Hosford, Lynn Symonds et al. · Breast Cancer Research and Treatment · 2014 · 15 citations · Full text

Medicine, Oncology, Pharmacology +13

A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer

Lynn Symonds, Isaac Jenkins, Hannah M. Linden et al. · Clinical Breast Cancer · 2021 · 12 citations · Full text

Medicine, Oncology, Pharmacology +17